



1FW

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
October 26, 2004 Date	 Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: ANTI-VEGF ANTIBODY PRODRUG
METHODS (As Amended)

Group Art Unit: 1642

Examiner: Yaen, C.

Atty. Dkt. No.: 3999.002587

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the documents listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be due in connection herewith. Even if an Official Action had been issued in the last few days, no fees would be required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a foreign counterpart to the present application. The listed documents were provided by European legal representatives of another party in connection with their defense to an Opposition filed against their European patent by the licensee of the present application. Receipt of the listed documents began on about August 23, 2004, and was completed on about August 27, 2004, and the present statement is being filed within three months of the first receipt of the listed documents.

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002587.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: October 26, 2004

Form PTO-1449 (modified)

Atty. Docket No.

3999.002587

Serial No.

10/738,404

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Thorpe and Brekken

Filing Date:

December 17, 2003

Group:

1642

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Pages 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C152	Ben-Hur and Orenstein, "The Endothelium and Red Blood Cell as Potential Targets in PDT-Induced Vascular Stasis," <i>J. Radiat. Biol.</i> , 60(1/2):293-301, 1991.
	C153	Folkman, "Tumor Angiogenesis," <i>Adv. Cancer Res.</i> , 43:175-203, 1985.
	C154	Gschwind <i>et al.</i> , "The Discovery of Receptor Tyrosine Kinases: Targets for Cancer Therapy," <i>Nature Reviews/Cancer</i> , 4:361-370, 2004.
	C155	Martiny-Baron and Marmé, "VEGF-Mediated Tumour Angiogenesis: A New Target for Cancer Therapy," <i>Curr. Opin. Biotech.</i> , 6:675-680, 1995.
	C156	McDonald and Baluk, "Significance of Blood Vessel Leakiness in Cancer," <i>Cancer Research</i> , 62:5381-5385, 2002.
	C157	Murata <i>et al.</i> , "Immunohistochemical Detection of Extravasated Fibrinogen (Fibrin) in Human Diabetic Retina," <i>Graefe's Arch. Clin. Exp. Ophthalmol.</i> , 230:428-431, 1992.
	C158	Risau, "What, if anything, is an Angiogenic Factor?" <i>Cancer Metastasis Rev.</i> , 15:149-151, 1996.
	C159	Senger <i>et al.</i> , "Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid," <i>Science</i> , 219:983-985, 1983.
	C160	Sioussat <i>et al.</i> , "Inhibition of Vascular Permeability Factor (Vascular Endothelial Growth Factor) with Antipeptide Antibodies," <i>Arch. Biochem. Biophys.</i> , 301(1):15-20, 1993.
	C161	Wiig <i>et al.</i> , "Interstitial Fluid Pressure in DMBA-Induced Rat Mammary Tumours," <i>Scand. J. Clin. Lab. Invest.</i> , 42:159-164, 1982.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

